South San Francisco, CA — April 16, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra…Original Article
FDA Grants Breakthrough Therapy Designation For Genentech’s Hemlibra (emicizumab-kxwh) in Hemophilia A Without Inhibitors
